Protein Kinase Inhibitors

Kinase Inhibitor

Idiopathic Pulmonary Fibrosis

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>OFEV capsules contain nintedanib, a kinase inhibitor [see <a href="#S12.1">Mechanism of Action (12.1)</a>]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-,methyl ester, (3Z)-, ethanesulfonate (1:1).Its structural formula is:<img alt="Chemical Structure" src="ofev-01.jpg"/>Nintedanib esylate is a bright yellow powder with an empirical formula of C31H33N5O4∙C2H6O3S and a molecular weight of 649.76 g/mol.OFEV capsules for oral administration are available in 2 dose strengths containing 100 mg or 150 mg of nintedanib (equivalent to 120.40 mg or 180.60 mg nintedanib ethanesulfonate, respectively). The inactive ingredients of OFEV are the following: Fill Material: triglycerides, hard fat, lecithin. Capsule Shell: gelatin, glycerol, titanium dioxide, red ferric oxide, yellow ferric oxide, black ink.</section>

Ofev

nintedanib

nintedanib 100 MG Oral Capsule

nintedanib 100 MG Oral Capsule [Ofev]

nintedanib 150 MG Oral Capsule

nintedanib 150 MG Oral Capsule [Ofev]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Pharmacy List 

Reimbursement Information

Coverage Authorization Request 

Coverage Authorization Appeals - Physican: IPF

Coverage Authorization Appeals - Patient: IPF

Letter of Medical Necessity - Physician: IPF

Letter of Medical Necessity - Patient: IPF 

PA Tips & Checklist: IPF

PA Tips & Checklist - Spanish: IPF

Appeals Tips & Checklist: IPF

Appeals Tips & Checklist - Spanish: IPF

Coverage Authorization Appeal - Physician: SSc-ILD

Coverage Authorization Appeals - Patient: SSc-ILD

Letter of Medical Exception: SSc-ILD

Letter of Medical Necessity: SSc-ILD

Coverage Authorization Appeals - Physician: Chronic Fibrosing ILDs with a Progressive Phenotype

Coverage Authorization Appeals - Patient: Chronic Fibrosing ILDs with a Progressive Phenotype

Letter of Medical Necessity: Chronic Fibrosing ILDs with a Progressive Phenotype

Letter of Medical Exception: Chronic Fibrosing ILDs with a Progressive Phenotype

Enroll in Patient Savings Program 

BI Cares Patient Assistance Program Application

Bridge Program 

Ofev Prescription Form 

Other HCP Resources: Patient Support 

Open Doors Patient Support Program and Boehringer Ingelheim Clinical Educator Enrollment Form

Open Doors Patient Support Program and Boehringer Ingelheim Clinical Educator Enrollment Form - Online

Open Doors Patient Support Program and Boehringer Ingelheim Clinical Educator Enrollment Form - Online (Spanish)